{"id":"fulvestrant-injection","safety":{"commonSideEffects":[{"effect":"Nausea","drugRate":"38.7%","placeboRate":"","totalAtRisk":1359,"totalAffected":526,"trialsReporting":5},{"effect":"Diarrhoea","drugRate":"33.9%","placeboRate":"","totalAtRisk":1359,"totalAffected":461,"trialsReporting":5},{"effect":"Fatigue","drugRate":"25.8%","placeboRate":"","totalAtRisk":1359,"totalAffected":350,"trialsReporting":5},{"effect":"Arthralgia","drugRate":"21.6%","placeboRate":"","totalAtRisk":1359,"totalAffected":294,"trialsReporting":5},{"effect":"Vomiting","drugRate":"25.7%","placeboRate":"","totalAtRisk":1131,"totalAffected":291,"trialsReporting":4},{"effect":"Hyperglycaemia","drugRate":"25.7%","placeboRate":"","totalAtRisk":1131,"totalAffected":291,"trialsReporting":4},{"effect":"Neutropenia","drugRate":"46.6%","placeboRate":"","totalAtRisk":610,"totalAffected":284,"trialsReporting":2},{"effect":"Decreased appetite","drugRate":"23.7%","placeboRate":"","totalAtRisk":1131,"totalAffected":268,"trialsReporting":4},{"effect":"Rash","drugRate":"27.5%","placeboRate":"","totalAtRisk":894,"totalAffected":246,"trialsReporting":3},{"effect":"Headache","drugRate":"17.8%","placeboRate":"","totalAtRisk":1359,"totalAffected":242,"trialsReporting":5},{"effect":"Back pain","drugRate":"15.9%","placeboRate":"","totalAtRisk":1359,"totalAffected":216,"trialsReporting":5},{"effect":"Constipation","drugRate":"15.1%","placeboRate":"","totalAtRisk":1359,"totalAffected":205,"trialsReporting":5},{"effect":"Cough","drugRate":"14.9%","placeboRate":"","totalAtRisk":1359,"totalAffected":203,"trialsReporting":5},{"effect":"Asthenia","drugRate":"16.2%","placeboRate":"","totalAtRisk":1131,"totalAffected":183,"trialsReporting":4},{"effect":"Pruritus","drugRate":"20.2%","placeboRate":"","totalAtRisk":894,"totalAffected":181,"trialsReporting":3},{"effect":"Alopecia","drugRate":"19.6%","placeboRate":"","totalAtRisk":894,"totalAffected":175,"trialsReporting":3},{"effect":"Stomatitis","drugRate":"18.7%","placeboRate":"","totalAtRisk":894,"totalAffected":167,"trialsReporting":3},{"effect":"Anaemia","drugRate":"12.0%","placeboRate":"","totalAtRisk":1359,"totalAffected":163,"trialsReporting":5},{"effect":"Aspartate aminotransferase increased","drugRate":"11.9%","placeboRate":"","totalAtRisk":1359,"totalAffected":162,"trialsReporting":5},{"effect":"Dyspnoea","drugRate":"11.7%","placeboRate":"","totalAtRisk":1359,"totalAffected":159,"trialsReporting":5},{"effect":"Alanine aminotransferase increased","drugRate":"11.5%","placeboRate":"","totalAtRisk":1359,"totalAffected":156,"trialsReporting":5},{"effect":"Pain in extremity","drugRate":"11.4%","placeboRate":"","totalAtRisk":1359,"totalAffected":155,"trialsReporting":5},{"effect":"Oedema peripheral","drugRate":"12.2%","placeboRate":"","totalAtRisk":1122,"totalAffected":137,"trialsReporting":4},{"effect":"Pyrexia","drugRate":"15.0%","placeboRate":"","totalAtRisk":894,"totalAffected":134,"trialsReporting":3},{"effect":"Dyspepsia","drugRate":"11.6%","placeboRate":"","totalAtRisk":1131,"totalAffected":131,"trialsReporting":4},{"effect":"Hot flush","drugRate":"10.6%","placeboRate":"","totalAtRisk":1232,"totalAffected":131,"trialsReporting":4},{"effect":"Hypertension","drugRate":"9.6%","placeboRate":"","totalAtRisk":1359,"totalAffected":131,"trialsReporting":5},{"effect":"Insomnia","drugRate":"9.3%","placeboRate":"","totalAtRisk":1359,"totalAffected":127,"trialsReporting":5},{"effect":"Weight decreased","drugRate":"13.9%","placeboRate":"","totalAtRisk":894,"totalAffected":124,"trialsReporting":3},{"effect":"Urinary tract infection","drugRate":"10.6%","placeboRate":"","totalAtRisk":1131,"totalAffected":120,"trialsReporting":4},{"effect":"Abdominal pain","drugRate":"9.8%","placeboRate":"","totalAtRisk":1131,"totalAffected":111,"trialsReporting":4},{"effect":"Myalgia","drugRate":"7.8%","placeboRate":"","totalAtRisk":1359,"totalAffected":106,"trialsReporting":5},{"effect":"Dizziness","drugRate":"11.9%","placeboRate":"","totalAtRisk":894,"totalAffected":106,"trialsReporting":3},{"effect":"Dry skin","drugRate":"11.9%","placeboRate":"","totalAtRisk":894,"totalAffected":106,"trialsReporting":3},{"effect":"Neutrophil count decreased","drugRate":"21.7%","placeboRate":"","totalAtRisk":483,"totalAffected":105,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"11.5%","placeboRate":"","totalAtRisk":894,"totalAffected":103,"trialsReporting":3},{"effect":"Blood creatinine increased","drugRate":"10.6%","placeboRate":"","totalAtRisk":894,"totalAffected":95,"trialsReporting":3},{"effect":"Abdominal pain upper","drugRate":"10.5%","placeboRate":"","totalAtRisk":894,"totalAffected":94,"trialsReporting":3},{"effect":"Leukopenia","drugRate":"19.3%","placeboRate":"","totalAtRisk":483,"totalAffected":93,"trialsReporting":1},{"effect":"Bone pain","drugRate":"7.3%","placeboRate":"","totalAtRisk":1131,"totalAffected":83,"trialsReporting":4},{"effect":"Upper respiratory tract infection","drugRate":"8.9%","placeboRate":"","totalAtRisk":894,"totalAffected":80,"trialsReporting":3},{"effect":"Gamma-glutamyltransferase increased","drugRate":"8.3%","placeboRate":"","totalAtRisk":894,"totalAffected":74,"trialsReporting":3},{"effect":"Muscle spasms","drugRate":"8.3%","placeboRate":"","totalAtRisk":894,"totalAffected":74,"trialsReporting":3},{"effect":"Dry mouth","drugRate":"7.6%","placeboRate":"","totalAtRisk":894,"totalAffected":68,"trialsReporting":3},{"effect":"White blood cell count decreased","drugRate":"13.7%","placeboRate":"","totalAtRisk":483,"totalAffected":66,"trialsReporting":1},{"effect":"Dysgeusia","drugRate":"13.9%","placeboRate":"","totalAtRisk":411,"totalAffected":57,"trialsReporting":2},{"effect":"Rash maculo-papular","drugRate":"13.4%","placeboRate":"","totalAtRisk":411,"totalAffected":55,"trialsReporting":2},{"effect":"Erythema","drugRate":"6.0%","placeboRate":"","totalAtRisk":894,"totalAffected":54,"trialsReporting":3},{"effect":"Mucosal inflammation","drugRate":"18.7%","placeboRate":"","totalAtRisk":284,"totalAffected":53,"trialsReporting":1},{"effect":"Anxiety","drugRate":"6.5%","placeboRate":"","totalAtRisk":711,"totalAffected":46,"trialsReporting":2}]},"_chembl":null,"allNames":"fulvestrant injection","_dailymed":null,"mechanism":{"target":"ESR1","drugClass":"Estrogen receptor antagonist","explanation":"Fulvestrant works by attaching to estrogen receptors in breast cancer cells, which causes these receptors to break down. This prevents the cancer cells from growing and spreading.","oneSentence":"Fulvestrant binds to estrogen receptors in breast cancer cells, leading to their degradation and inhibiting tumor growth."},"_scrapedAt":"2026-03-28T01:47:51.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:48:22.654765+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07354022","phase":"PHASE3","title":"A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-04","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":912},{"nctId":"NCT07498478","phase":"PHASE2","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","status":"RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-03-17","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":"Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":392},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT07109726","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","status":"RECRUITING","sponsor":"Terremoto Biosciences Inc.","startDate":"2025-09-23","conditions":"Breast Cancer, Endometrial Cancer, Ovarian Cancer","enrollment":205},{"nctId":"NCT00099437","phase":"PHASE3","title":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2005-02-13","conditions":"Breast Cancer","enrollment":736},{"nctId":"NCT07226349","phase":"PHASE1","title":"A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-12-11","conditions":"Advanced Solid Tumor","enrollment":105},{"nctId":"NCT06120283","phase":"PHASE1","title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2023-12-01","conditions":"Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT07038369","phase":"PHASE1","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atavistik Bio, Inc","startDate":"2025-07-29","conditions":"Advanced Solid Tumors, Breast Cancer, Breast Carcinoma","enrollment":134},{"nctId":"NCT06993844","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ensem Therapeutics","startDate":"2025-06-10","conditions":"Advanced Solid Tumors, Advanced Breast Cancer","enrollment":233},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07368998","phase":"PHASE2","title":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-02-18","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT06736704","phase":"PHASE1, PHASE2","title":"SNV4818 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pikavation Therapeutics, Inc.","startDate":"2025-02-20","conditions":"Advanced Solid Tumors","enrollment":320},{"nctId":"NCT07287917","phase":"PHASE1, PHASE2","title":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Aminex Therapeutics, Inc.","startDate":"2026-01-26","conditions":"Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer","enrollment":92},{"nctId":"NCT04862663","phase":"PHASE3","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":895},{"nctId":"NCT04572295","phase":"PHASE1","title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-09","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT03531645","phase":"PHASE2","title":"Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-13","conditions":"Malignant Neoplasms of Female Genital Organs","enrollment":18},{"nctId":"NCT06257264","phase":"PHASE1","title":"A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-03-11","conditions":"Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer","enrollment":258},{"nctId":"NCT05154487","phase":"PHASE2","title":"A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GOG Foundation","startDate":"2024-09-11","conditions":"Endometroid Endometrial Cancer","enrollment":51},{"nctId":"NCT01560416","phase":"PHASE2","title":"Fulvestrant With or Without Ganetespib in HR+ Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-06","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT07389733","phase":"PHASE1, PHASE2","title":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-02","conditions":"Advanced Unresectable or Metastatic Breast Cancer of Adults","enrollment":180},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT01602380","phase":"PHASE3","title":"A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-10-17","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":462},{"nctId":"NCT07426822","phase":"PHASE2","title":"Rash & Diarrhea Prophylaxis With Capivasertib","status":"NOT_YET_RECRUITING","sponsor":"Maryam Lustberg","startDate":"2026-04","conditions":"Metastatic HR+/HER2- Breast Cancer","enrollment":108},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT06494150","phase":"PHASE2","title":"Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2024-12-26","conditions":"Low Grade Ovarian Serous Adenocarcinoma","enrollment":37},{"nctId":"NCT05038735","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-17","conditions":"Breast Cancer","enrollment":212},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT02947685","phase":"PHASE3","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-06-21","conditions":"HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer","enrollment":518},{"nctId":"NCT05101564","phase":"PHASE2","title":"Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Jennifer Lee Caswell-Jin","startDate":"2023-03-20","conditions":"Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer","enrollment":19},{"nctId":"NCT06995482","phase":"PHASE1","title":"Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers","status":"RECRUITING","sponsor":"Kashiv BioSciences, LLC","startDate":"2025-08-18","conditions":"Healthy Postmenopausal Women","enrollment":40},{"nctId":"NCT05501886","phase":"PHASE3","title":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celcuity Inc","startDate":"2022-12-08","conditions":"Breast Cancer","enrollment":701},{"nctId":"NCT07393321","phase":"PHASE3","title":"A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2026-02-10","conditions":"HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer","enrollment":210},{"nctId":"NCT04305496","phase":"PHASE3","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-04-16","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":818},{"nctId":"NCT05305924","phase":"PHASE2","title":"Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-02-25","conditions":"ER-Positive Breast Cancer, HER2-negative Breast Cancer","enrollment":28},{"nctId":"NCT07024173","phase":"PHASE3","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-07-23","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT07366632","phase":"PHASE1","title":"A Study of Single Dose of BL0175 in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-01-26","conditions":"Postmenopausal Women","enrollment":27},{"nctId":"NCT03289039","phase":"PHASE2","title":"Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-10-25","conditions":"Breast Cancer","enrollment":21},{"nctId":"NCT07358377","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor","status":"NOT_YET_RECRUITING","sponsor":"Atridia Pty Ltd.","startDate":"2026-03-15","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT05933395","phase":"PHASE2","title":"Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-09-23","conditions":"Advanced Breast Cancer","enrollment":135},{"nctId":"NCT05860465","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-09-08","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":254},{"nctId":"NCT07340619","phase":"PHASE2","title":"Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-18","conditions":"Metastatic (Stage IV) Melanoma","enrollment":51},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT06764186","phase":"PHASE3","title":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-07","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":101},{"nctId":"NCT07330544","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-24","conditions":"Breast Cancer","enrollment":118},{"nctId":"NCT05365178","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-07-01","conditions":"HR-positive, HER2-negative Breast Neoplasms","enrollment":432},{"nctId":"NCT05963984","phase":"PHASE2","title":"A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants","status":"COMPLETED","sponsor":"Carrick Therapeutics Limited","startDate":"2023-11-16","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer","enrollment":60},{"nctId":"NCT06849947","phase":"PHASE2","title":"Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Yeon Hee Park","startDate":"2026-02-01","conditions":"Breast Cancer Metastatic","enrollment":272},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT04556773","phase":"PHASE1","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-17","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT06851442","phase":"PHASE1, PHASE2","title":"Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-05-16","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT06369285","phase":"PHASE2","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Puma Biotechnology, Inc.","startDate":"2024-11-19","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":150},{"nctId":"NCT02738866","phase":"PHASE2","title":"Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-10-25","conditions":"Metastatic Breast Cancer","enrollment":60},{"nctId":"NCT05631795","phase":"PHASE4","title":"Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-09","conditions":"Advanced Breast Cancer","enrollment":40},{"nctId":"NCT01992952","phase":"PHASE1, PHASE2","title":"Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Velindre NHS Trust","startDate":"2014-05-07","conditions":"Estrogen Receptor Positive Breast Cancer","enrollment":149},{"nctId":"NCT04214288","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-04-22","conditions":"Advanced ER-Positive HER2-Negative Breast Cancer","enrollment":240},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":"Metastatic Breast Cancer","enrollment":1017},{"nctId":"NCT05041842","phase":"PHASE2","title":"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2021-12-17","conditions":"Metastatic Breast Cancer With a Isolated Brain Progression","enrollment":53},{"nctId":"NCT03363893","phase":"PHASE1, PHASE2","title":"Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"Carrick Therapeutics Limited","startDate":"2017-11-14","conditions":"Advanced Solid Malignancies","enrollment":124},{"nctId":"NCT06756932","phase":"PHASE1","title":"BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-02-04","conditions":"Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT03620643","phase":"PHASE2","title":"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2019-05-09","conditions":"Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer","enrollment":33},{"nctId":"NCT05608252","phase":"PHASE1, PHASE2","title":"VS-6766+Abema+Fulv in Met HR+/HER- BC","status":"RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2023-02-23","conditions":"Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":63},{"nctId":"NCT05090358","phase":"PHASE2","title":"Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-08","conditions":"Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT03147287","phase":"PHASE2","title":"Palbociclib After CDK and Endocrine Therapy (PACE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-09-05","conditions":"Metastatic Breast Cancer","enrollment":220},{"nctId":"NCT03959891","phase":"PHASE1","title":"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-05-30","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT06680921","phase":"PHASE3","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":460},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT03778931","phase":"PHASE3","title":"Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2019-05-10","conditions":"Breast Cancer","enrollment":478},{"nctId":"NCT06239467","phase":"PHASE1","title":"First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer","status":"RECRUITING","sponsor":"OnKure, Inc.","startDate":"2024-02-26","conditions":"Advanced Cancer, Breast Cancer, Advanced Solid Tumors","enrollment":200},{"nctId":"NCT05113368","phase":"PHASE2","title":"Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Sarah K. Lynam MD","startDate":"2022-06-28","conditions":"Ovarian Cancer, Serous Ovarian Cancer","enrollment":31},{"nctId":"NCT04224272","phase":"PHASE2","title":"A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2020-06-10","conditions":"HER2+/HR+ Breast Cancer","enrollment":51},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT06208410","phase":"PHASE1, PHASE2","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2024-01-11","conditions":"Advanced Solid Tumors","enrollment":306},{"nctId":"NCT05181033","phase":"PHASE2","title":"Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2021-12-27","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT03767335","phase":"PHASE1","title":"MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Menarini Group","startDate":"2018-11-13","conditions":"Advanced or Metastatic Breast Cancer","enrollment":62},{"nctId":"NCT03099174","phase":"PHASE1","title":"This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-05-04","conditions":"Neoplasms, Breast Neoplasms","enrollment":133},{"nctId":"NCT04544189","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-20","conditions":"Breast Neoplasms","enrollment":69},{"nctId":"NCT06515470","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Biotheryx, Inc.","startDate":"2024-07-03","conditions":"Breast Cancer","enrollment":82},{"nctId":"NCT06253195","phase":"PHASE1","title":"BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2024-04-01","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer","enrollment":33},{"nctId":"NCT06998108","phase":"PHASE3","title":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2022-06-09","conditions":"HR+/HER2- Locally Advanced, Metastatic Breast Cancer","enrollment":330},{"nctId":"NCT05251714","phase":"PHASE1, PHASE2","title":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Treadwell Therapeutics, Inc","startDate":"2022-05-27","conditions":"Advanced Solid Tumor, Breast Cancer","enrollment":44},{"nctId":"NCT05759949","phase":"PHASE1","title":"First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors","status":"COMPLETED","sponsor":"Relay Therapeutics, Inc.","startDate":"2023-03-29","conditions":"PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer","enrollment":41},{"nctId":"NCT05319873","phase":"PHASE1, PHASE2","title":"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-04-07","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":18},{"nctId":"NCT06957379","phase":"PHASE2","title":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-29","conditions":"HR+/HER2- Advanced/Metastatic Breast Cancer","enrollment":78},{"nctId":"NCT06954961","phase":"PHASE3","title":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2022-09-15","conditions":"Breast Cancer","enrollment":640},{"nctId":"NCT06837792","phase":"PHASE2","title":"Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-10-01","conditions":"Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)","enrollment":141},{"nctId":"NCT06950086","phase":"PHASE1, PHASE2","title":"Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TYK Medicines, Inc","startDate":"2024-01-02","conditions":"HR-positive, HER2-negative Advanced Breast Cancer","enrollment":180},{"nctId":"NCT06941142","phase":"PHASE1","title":"A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-04-30","conditions":"Advanced Breast Cancer","enrollment":382},{"nctId":"NCT06929325","phase":"PHASE3","title":"Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-04","conditions":"HR+/HER2- Advanced/Metastatic Breast Cancer","enrollment":312},{"nctId":"NCT06431243","phase":"PHASE1, PHASE2","title":"A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-05-08","conditions":"Advanced Solid Tumor","enrollment":132},{"nctId":"NCT06607757","phase":"PHASE2","title":"Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer","status":"RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2024-12-04","conditions":"CCCA Assessed by Ki67 Drop Below <2.7% From Baseline","enrollment":120},{"nctId":"NCT04053322","phase":"PHASE2","title":"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2019-08-26","conditions":"ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status","enrollment":172},{"nctId":"NCT02206984","phase":"PHASE2","title":"Endocrine Response in Women With Invasive Lobular Breast Cancer","status":"COMPLETED","sponsor":"Priscilla McAuliffe","startDate":"2015-09-30","conditions":"Breast Cancer","enrollment":201},{"nctId":"NCT03820830","phase":"PHASE3","title":"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-08-27","conditions":"Breast Cancer Recurrent","enrollment":405},{"nctId":"NCT06856200","phase":"NA","title":"A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-28","conditions":"Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy","enrollment":36},{"nctId":"NCT02437318","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-23","conditions":"Breast Cancer","enrollment":572},{"nctId":"NCT03854903","phase":"PHASE1","title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2019-04-01","conditions":"Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer","enrollment":19},{"nctId":"NCT04872166","phase":"PHASE1","title":"A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer","status":"RECRUITING","sponsor":"Edgewood Oncology Inc.","startDate":"2021-06-07","conditions":"Advanced Solid Tumor, Metastatic Breast Cancer","enrollment":112}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"INJECTION SITE PAIN"},{"count":5,"reaction":"FATIGUE"},{"count":5,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":5,"reaction":"NEOPLASM PROGRESSION"},{"count":4,"reaction":"DYSPNOEA"},{"count":4,"reaction":"NAUSEA"},{"count":4,"reaction":"PAIN IN EXTREMITY"},{"count":4,"reaction":"PLATELET COUNT DECREASED"},{"count":3,"reaction":"ASTHENIA"},{"count":3,"reaction":"EPISTAXIS"}],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Fulvestrant injection","genericName":"fulvestrant-injection","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":24,"withResults":6},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:48:22.654765+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}